Peter Tebben, MD
Cards
About
Departments & Organizations
Education & Training
- Fellow
- Mayo Clinic (2006)
- Fellow
- Mayo Clinic (2004)
- Resident
- University of Minnesota (2002)
- MD
- University of Kansas (1998)
- BS
- University of Kansas (1994)
- BS
- Kansas State University (1991)
Research
Publications
2024
9295 Characteristics Of Adults with Autosomal Dominant Hypocalcemia Type 1 (ADH1) Enrolled In The CLARIFY Disease Monitoring Study
Ing S, Harmatz P, Mora S, Imel E, Tebben P, Warren M, Ma N, Khan A, Palermo A, Decallonne B, Lemoine S, Mantovani G, Linglart A, Wasserman H, Barbosa A, Cardot-Bauters C, Roberts M, Mathew A, Adler S, Zillikens M, Clifton-Bligh R, Rejnmark L. 9295 Characteristics Of Adults with Autosomal Dominant Hypocalcemia Type 1 (ADH1) Enrolled In The CLARIFY Disease Monitoring Study. Journal Of The Endocrine Society 2024, 8: bvae163.383. PMCID: PMC11454366, DOI: 10.1210/jendso/bvae163.383.Peer-Reviewed Original Research8669 Characteristics Of Adults with Autosomal Dominant Hypocalcemia Type 1 (ADH1) Enrolled In The CLARIFY Disease Monitoring Study
Ing S, Harmatz P, Mora S, Imel E, Tebben P, Warren M, Ma N, Khan A, Palermo A, Decallonne B, Lemoine S, Mantovani G, Linglart A, Wasserman H, Barbosa A, Cardot-Bauters C, Roberts M, Mathew A, Adler S, Zillikens M, Clifton-Bligh R, Rejnmark L. 8669 Characteristics Of Adults with Autosomal Dominant Hypocalcemia Type 1 (ADH1) Enrolled In The CLARIFY Disease Monitoring Study. Journal Of The Endocrine Society 2024, 8: bvae163.384. PMCID: PMC11454712, DOI: 10.1210/jendso/bvae163.384.Peer-Reviewed Original ResearchErratum to “An update on clinical presentation and responses to therapy of patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH).” Kidney International 2023;105:1058–1076
Zhu Z, Bo-Ran Ho B, Chen A, Amrhein J, Apetrei A, Carpenter T, Lazaretti-Castro M, Colazo J, McCrystal Dahir K, Geßner M, Gurevich E, Heier C, Simmons J, Hunley T, Hoppe B, Jacobsen C, Kouri A, Ma N, Majumdar S, Molin A, Nokoff N, Ott S, Peña H, Santos F, Tebben P, Topor L, Deng Y, Bergwitz C. Erratum to “An update on clinical presentation and responses to therapy of patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH).” Kidney International 2023;105:1058–1076. Kidney International 2024, 106: 159. PMID: 38906648, DOI: 10.1016/j.kint.2024.05.005.Peer-Reviewed Original ResearchCALIBRATE: A phase 3, randomized, open-label study evaluating the efficacy and safety of encaleret (CLTX-305) compared to standard of care in participants with autosomal dominant hypocalcemia type 1 [NCT05680818]
Rejnmark L, Mannstadt M, Brandi M, Ozono K, Tebben P, Mathew A, Roberts M, Adler S, Gafni R. CALIBRATE: A phase 3, randomized, open-label study evaluating the efficacy and safety of encaleret (CLTX-305) compared to standard of care in participants with autosomal dominant hypocalcemia type 1 [NCT05680818]. Endocrine Abstracts 2024 DOI: 10.1530/endoabs.99.oc2.6.Peer-Reviewed Original ResearchCorrection: Implementation of genomic medicine for rare disease in a tertiary healthcare system: Mayo Clinic Program for Rare and Undiagnosed Diseases (PRaUD)
Pinto e Vairo F, Kemppainen J, Vitek C, Whalen D, Kolbert K, Sikkink K, Kroc S, Kruisselbrink T, Shupe G, Knudson A, Burke E, Loftus E, Bandel L, Prochnow C, Mulvihill L, Thomas B, Gable D, Graddy C, Garzon G, Ekpoh I, Porquera E, Fervenza F, Hogan M, El Ters M, Warrington K, Davis J, Koster M, Orandi A, Basiaga M, Vella A, Kumar S, Creo A, Lteif A, Pittock S, Tebben P, Abate E, Joshi A, Ristagno E, Patnaik M, Schimmenti L, Dhamija R, Sabrowsky S, Wierenga K, Keddis M, Samadder N, Presutti R, Robinson S, Stephens M, Roberts L, Faubion W, Driscoll S, Wong-Kisiel L, Selcen D, Flanagan E, Ramanan V, Jackson L, Mauermann M, Ortega V, Anderson S, Aoudia S, Klee E, McAllister T, Lazaridis K. Correction: Implementation of genomic medicine for rare disease in a tertiary healthcare system: Mayo Clinic Program for Rare and Undiagnosed Diseases (PRaUD). Journal Of Translational Medicine 2024, 22: 400. PMID: 38689323, PMCID: PMC11061992, DOI: 10.1186/s12967-024-05185-9.Peer-Reviewed Original ResearchAn infant developing hypercalcemia and hypophosphatemia due to the use of exclusively almond milk
Salama M, Tebben P, Al Nofal A. An infant developing hypercalcemia and hypophosphatemia due to the use of exclusively almond milk. Journal Of Pediatric Endocrinology And Metabolism 2024, 37: 375-379. PMID: 38414167, DOI: 10.1515/jpem-2023-0494.Peer-Reviewed Case Reports and Technical NotesConceptsParathyroid hormoneCreatinine ratioUrine calcium-to-creatinine ratioHistory of biliary atresiaCalcium to creatinine ratioMonths prior to presentationAlmond milkCow's milk allergyMilk consumptionMonths of ageSevere hypercalcemiaBiliary atresiaAlternative to cow milkCow's milkD levelsLiver transplantationPlant-based milk alternativesCase reportInitial managementIntravenous fluidsMilk allergyHypercalcemiaMineral contentCalcium concentrationHypophosphatemiaEfficacy of Oral Cinacalcet in Non-PTH Nonmalignant Hypercalcemia from Excess 1,25-Dihydroxyvitamin D
Mohan S, Sheehan M, Tebben P, Wermers R. Efficacy of Oral Cinacalcet in Non-PTH Nonmalignant Hypercalcemia from Excess 1,25-Dihydroxyvitamin D. JCEM Case Reports 2024, 2: luae022. PMID: 38476635, PMCID: PMC10928506, DOI: 10.1210/jcemcr/luae022.Peer-Reviewed Original ResearchLow PTHTherapeutic optionsCalcium levelsNormalization of calcium levelsElevated serum calcium levelsSerum calcium levelsMechanism(s) of actionOral cinacalcetSymptomatic hypocalcemiaCinacalcet doseRecurrent nephrolithiasisUrine calciumRare causeGranulomatous diseaseCinacalcetHypercalcemiaFollow-upSymptomatic benefitGenetic testingBiallelic variantsGenetic mutationsMechanism(s)Mild decreasePTHMalignancyAn update on clinical presentation and responses to therapy of patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH)
Zhu Z, Bo-Ran Ho B, Chen A, Amrhein J, Apetrei A, Carpenter T, Lazaretti-Castro M, Colazo J, McCrystal Dahir K, Geßner M, Gurevich E, Heier C, Simmons J, Hunley T, Hoppe B, Jacobsen C, Kouri A, Ma N, Majumdar S, Molin A, Nokoff N, Ott S, Peña H, Santos F, Tebben P, Topor L, Deng Y, Bergwitz C. An update on clinical presentation and responses to therapy of patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH). Kidney International 2024, 105: 1058-1076. PMID: 38364990, PMCID: PMC11106756, DOI: 10.1016/j.kint.2024.01.031.Peer-Reviewed Original ResearchResponse to therapyHereditary hypophosphatemic ricketsPathogenic variantsBone phenotypeSerum phosphateHypophosphatemic ricketsHeterozygous carriersPartial response to therapyPredicting response to therapyRare group of disordersIntact parathyroid hormoneUrine calcium excretionCorrection of hypophosphatemiaSolute carrier familyDecreased serum phosphateBaseline disease severityVariants in vitroOral phosphate supplementationNormalize serum phosphateStandard of careGroup of disordersMutant allelesCarrier familyBiochemical phenotypeKidney phenotypeVitamin D and the kidney
Kritmetapak K, Tebben PJ, Kumar R. Vitamin d and the kidney. In: Hewison M; Et al editors., Feldman and Pike's vitamin d: biochemistry, physiology and diagnostics. Fifth Edition. London: Academic Press/Elsevier; 2024. vol. One. p. 301-30Chapters
2023
Primary hyperparathyroidism in patients with multiple endocrine neoplasia type 1: Impact of genotype and surgical approach on long-term postoperative outcomes
Shariq O, Abrantes V, Lu L, Tebben P, Foster T, Dy B, Lyden M, Young W, McKenzie T. Primary hyperparathyroidism in patients with multiple endocrine neoplasia type 1: Impact of genotype and surgical approach on long-term postoperative outcomes. Surgery 2023, 175: 8-16. PMID: 37891063, DOI: 10.1016/j.surg.2023.05.044.Peer-Reviewed Original ResearchConceptsMedian disease-free survivalDisease-free survivalPrimary hyperparathyroidismSurgical approachTruncated exon 2Total parathyroidectomyPostoperative outcomesExon 2Aggressive pNETsShorter median disease-free survivalHigh risk of recurrenceLong-term postoperative outcomesIncidence of postoperative hypoparathyroidismMultiple endocrine neoplasia type 1Incidence of permanent hypoparathyroidismPancreatic neuroendocrine tumorsAnalyzed baseline characteristicsRisk of recurrenceYounger median ageGermline pathogenic variantsHypoparathyroidism rateMEN1 genotypeMEN1 variantsPermanent hypoparathyroidismNeuroendocrine tumors
Academic Achievements & Community Involvement
Clinical Care
Overview
Clinical Specialties
Endocrinology; Pediatric Endocrinology & Diabetes
Fact Sheets
Low Bone Density
Learn More on Yale Medicine
Board Certifications
Pediatric Endocrinology
- Certification Organization
- AB of Pediatrics
- Original Certification Date
- 2007
Endocrinology Diabetes & Metabolism
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2005